The study, published in PLOS Pathogens by Yu Zhang, Peng Wang and colleagues at the People’s Hospital of Xinjiang Uygur Autonomous Region, focused on the viral gene K15, which sits at the right end of the KSHV genome and encodes a multi-pass transmembrane signaling protein. K15 exists in two highly divergent alleles, known as the prototype (P) and minority (M) forms. In their cytoplasmic signaling domains, the two variants share less than 33 percent amino acid homology, a degree of divergence that suggests they may engage different molecular partners inside infected cells and, potentially, shape disease in different ways.

Xinjiang, a historical crossroads on the Silk Road, offered an unusually informative setting. The region has a high prevalence of Kaposi sarcoma and co-circulating viral genotypes rarely seen together in Western cohorts. Of the 147 patients who passed quality control and genotyping, 107, or 72.8 percent, carried the K15M variant, while 40 carried K15P. That distribution echoes patterns reported in classic Kaposi sarcoma cohorts from Japan and Taiwan and hints that host genetic and evolutionary pressures in Central Asian populations may have favored the M form.

The clinical picture that emerged was striking and, at first glance, paradoxical. Patients carrying the M genotype were significantly less likely to be coinfected with HIV, at 10.3 percent versus 27.5 percent among P carriers, yet they showed higher levels of systemic inflammation, measured by the Systemic Immune-Inflammation Index (SII), the neutrophil-to-lymphocyte ratio, and neutrophil counts. They also suffered lower limb edema far more often, at 37.4 percent versus 20.0 percent, and were less likely to have mucosal involvement. After adjusting for tumor stage, demographics and CD4 T-cell counts, K15M carriage remained an independent predictor of edema, with 2.6-fold increased odds, and of a high inflammatory burden, with an adjusted odds ratio of 5.43 for elevated SII.

To probe whether inflammation actually lies on the causal path between viral genotype and edema, the team used causal mediation analysis, a statistical framework that decomposes an association into direct and indirect components. The Systemic Immune-Inflammation Index significantly mediated 29.0 percent of the genotype-associated effect on edema, with a P value of 0.009. A reverse mediation model, testing whether edema led to inflammation rather than the other way around, failed to reach significance, supporting inflammation’s position upstream in the pathway. Dose-response analysis sharpened the picture further: among K15M carriers, edema risk rose linearly with increasing SII, with an odds ratio of 1.58 per 500-unit increase, whereas no such gradient existed in K15P carriers. The inflammation-edema link, in other words, appears intrinsically tied to the viral genotype.

The mechanistic plausibility rests on the structure of the K15 protein. Its signaling capacity resides in a C-terminal cytoplasmic tail containing SH2- and SH3-binding motifs that recruit Src-family kinases and TRAF adaptor proteins to activate the pro-inflammatory NF-kB and MAPK pathways. The P form has been well characterized as mobilizing these cascades through specific tyrosine-based motifs. The M form, by contrast, shows reduced dependence on the canonical YEEV motif for NFAT activation, and the authors hypothesize that its structurally distinct tail may confer enhanced affinity for inflammatory adaptors or lack the negative regulatory phosphorylation sites present in the P type. Such differences could produce constitutive, unchecked signaling that sustains high-grade systemic inflammation, which in turn promotes vascular permeability and the tissue swelling that clinicians observe as edema.

The genotype also carried prognostic weight. Kaplan-Meier analysis showed significantly inferior progression-free survival among K15M carriers, with a log-rank P value of 0.017, and multivariate Cox modeling yielded an adjusted hazard ratio of 1.87, a borderline but robust estimate confirmed across multiple censoring scenarios in sensitivity analyses. Notably, the deleterious effect was most pronounced in patients with localized disease, where the hazard ratio reached 4.32, suggesting that viral biology can flag danger even when the tumor appears anatomically confined. A dedicated sensitivity analysis restricted to classic Kaposi sarcoma patients preserved the inflammatory signature of K15M, arguing against clinical subtype as a confounder.

To convert these biological insights into a usable clinical instrument, the researchers built a six-factor prognostic nomogram using LASSO Cox regression with cross-validation, maintaining an events-per-variable ratio of 11.2. The model anchors on the K15 genotype and visceral involvement, supplemented by CD4 count, procalcitonin, the lymphocyte-to-monocyte ratio and the neutrophil-to-lymphocyte ratio, the latter two selected over SII to avoid collinearity. The tool achieved a concordance index of 0.761, corrected to 0.743 after bootstrapping with 5,000 resamples, and time-dependent ROC analysis showed areas under the curve above 0.80 at one, two and three years.

The head-to-head comparison with conventional staging was decisive. The nomogram achieved an area under the curve of 0.830, significantly outperforming anatomical stage alone at 0.563 and visceral involvement alone at 0.530, with P values of 0.003 and below 0.001 respectively. Reclassification metrics confirmed substantial gains in predictive accuracy, and decision curve analysis demonstrated net clinical benefit across a wide range of threshold probabilities. When patients were stratified by nomogram score, the high-risk group showed a median progression-free survival of 11.0 months versus 40.0 months in the low-risk group, a separation with a P value below 0.0001 that held regardless of HIV status or tumor burden.

The authors are careful to frame their conclusions within the limits of a single-center, retrospective design. Edema was assessed qualitatively rather than with quantitative metrics, a small fraction of viral genotypes remained unclassified, possibly reflecting recombination or untyped variants, and the mediation results are presented as biologically plausible associations rather than definitive causal proof, since no wet-lab cytokine assays were performed on the archival samples. Even so, the implications are considerable. If the K15M genotype sustains an NF-kB-driven inflammatory program independent of immunodeficiency, then carriers may represent a subgroup amenable to anti-inflammatory or immunomodulatory strategies layered onto conventional therapy, with genotyping serving as a companion diagnostic. More broadly, the study argues that Kaposi sarcoma risk assessment should move from anatomical observation toward biology-driven precision oncology, incorporating the genetics of the virus itself into the clinical calculus, particularly in regions where the M genotype predominates.

Subject of Research: Association of KSHV K15 genetic variants with Kaposi sarcoma aggressiveness and inflammation

Article Title: KSHV K15 genetic heterogeneity is associated with Kaposi sarcoma aggressiveness through modulation of the host inflammatory microenvironment

Article References: Zhang, Y., Wang, P., Zhang, J., Wang, Y., Li, T., Ding, Y., & Kang, X. (2026). KSHV K15 genetic heterogeneity is associated with Kaposi sarcoma aggressiveness through modulation of the host inflammatory microenvironment. PLOS Pathogens, 22(10), e1014615. https://doi.org/10.1371/journal.ppat.1014615

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014615

Keywords: KSHV, Kaposi sarcoma, K15 genotype, inflammation, herpesvirus, edema, prognostic nomogram, precision oncology, mediation analysis, NF-kB, HIV, viral genotyping